ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
26 announcements
Hemo Organic Ltd allotted 34 lakh equity shares upon conversion of warrants to non-promoter entities. The company received Rs. 3.1875 Crore as the balance consideration.
Non-promoter Dharmendrabhai Becharbhai Jasani acquired 1,11,341 shares of Hemo Organic Ltd via on-market purchase, increasing his stake in the company.
Hemo Organic promoter Dineshbhai Shanabhai Patel sold 60,000 equity shares via an off-market transaction. This disposal reduced the promoter's stake from 6.49% to 4.76%.
Promoter Dineshbhai Shanabhai Patel sold 3.12 lakh shares of Hemo Organic Ltd via an off-market deal valued at ₹0.19 Crore.
Promoters of Hemo Organic are transferring 5.68 lakh shares (16.38% stake) to external buyers via an off-market Share Purchase Agreement for ₹0.34 Crore.
Promoters of Hemo Organic Ltd entered into separate Share Purchase Agreements to sell 5,67,958 equity shares in an off-market transaction. Financial consideration remains undisclosed.
Hemo Organic's Company Secretary and Compliance Officer, Ms. Yukta Prakash Patel, has resigned effective September 19, 2026, citing personal reasons.
Hemo Organic Ltd scheduled a board meeting for September 23, 2026, to discuss a proposal for raising funds through the issuance of securities.
Hemo Organic Ltd received the 2nd tranche of consideration worth ₹2.76 Crore for convertible warrants from non-promoter allottees, progressing towards future equity share conversion.
Hemo Organic Ltd appointed M/s V S S B & Associates as Statutory Auditors for a five-year term, following its 34th Annual General Meeting.
Hemo Organic Limited has appointed Mr. Ayush Dharmendrabhai Jasani as an Additional Director and Chairperson of the company, effective September 9, 2026.
Hemo Organic Ltd announced the appointment of Mr. Ayush Dharmendrabhai Jasani as Additional Director and Chairperson of the company, effective September 9, 2026.
Hemo Organic Limited held its 34th Annual General Meeting on September 8, 2026. The meeting discussed the adoption of financial statements and the appointment of directors/auditors.
Hemo Organic Limited submitted its Annual Report for FY 2025-26 and the Notice for its 34th Annual General Meeting scheduled for September 8, 2026.
Hemo Organic announced the appointment of a new statutory auditor and the scheduling of its 34th Annual General Meeting for September 8, 2026.
Hemo Organic Limited announced that its statutory auditor, M/s. M A A K & Associates, will retire upon the conclusion of the upcoming 34th Annual General Meeting.
Hemo Organic appointed M/s. Jitendra Parmer & Associates as Secretarial Auditor for FY2025-26 and M/s. Umesh Khese & Co. as Internal Auditor for FY2026-27.
Hemo Organic Ltd has filed its quarterly shareholding pattern for the period ended June 30, 2026. The report details the distribution of equity across various shareholder categories.
Hemo Organic Ltd reported a net loss of ₹0.1 Cr for Q1 FY27.
Hemo Organic scheduled a board meeting for July 15, 2026. The board will consider un-audited financial results for the June quarter.
Hemo Organic Limited reported an annual total income of ₹0.93 Crore for FY26. The auditor issued a modified opinion due to missing balance confirmations for key accounts.
Hemo Organic Ltd reported revenue from operations of ₹0.9 Cr (-62.5% YoY) and a net loss of ₹0.5 Cr for Q4 FY26.
Hemo Organic Limited reported audited financial results for the year ended March 31, 2026. The company recorded a net loss of ₹77.81 lakhs for the period.
Hemo Organic Limited scheduled a board meeting on May 29, 2026. Directors will consider and approve audited financial results for the quarter and year ended March 2026.
Hemo Organic Ltd submitted a declaration confirming it is not classified as a 'Large Corporate' for the financial year ended March 31, 2026. This follows SEBI's framework regarding fund raising through debt securities. The filing is a routine regulatory compliance update and has no material impact on current financial operations.
Hemo Organic Ltd reported a net loss of ₹0.2 Cr for Q3 FY26.